文献速递核素与放射性配体治疗放射性药物与辐射防护

[177Lu]Lu-satoreotide tetraxetan治疗晚期生长抑素受体阳性神经内分泌肿瘤的安全性及疗效的I/II期研究

A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-09-18

这项开放标签I/II期研究在40例经治进展期生长抑素受体阳性神经内分泌肿瘤患者中评估了新型SSTR拮抗剂[177Lu]Lu-satoreotide tetraxetan的安全性和疗效,并用剂量学指导最大给药活度。A部分15例接受固定活度4.5 GBq/300 μg×3周期,B部分25例接受1–5周期、活度4.5或6.0 GBq/周期、肽量300/700/1300 μg/周期,肾脏累积吸收剂量限23 Gy、骨髓限1.5 Gy。中位累积活度13.0 GBq(3周期),42.5%患者出现≥3级治疗相关不良事件,疾病控制率94.7%(95%CI 82.3–99.4),总缓解率21.1%(95%CI 9.6–37.3)。

要点

  • 中位累积给药活度13.0 GBq(3周期),A部分13.1 GBq、B部分12.9 GBq。
  • 42.5%患者发生≥3级治疗相关不良事件,最常见为淋巴细胞减少、血小板减少和中性粒细胞减少。
  • 疾病控制率94.7%(95%CI 82.3–99.4),总缓解率21.1%(95%CI 9.6–37.3)。

核心结论

  • [177Lu]Lu-satoreotide tetraxetan以中位累积活度13.0 GBq分3周期给药,在进展期SSTR阳性NET患者中安全性可接受且临床缓解令人期待。
  • 一项5年长期随访研究正在进行中。

研究设计与样本

  • 开放标签I/II期研究,共纳入40例既往经治、进展期生长抑素受体阳性神经内分泌肿瘤患者,用剂量学指导最大给药活度。
  • A部分15例接受固定活度4.5 GBq/300 μg每周期、共3周期。
  • B部分25例接受1–5周期,评估4.5或6.0 GBq/周期及300、700或1300 μg/周期肽量,肾脏累积吸收剂量限23 Gy、骨髓限1.5 Gy。
  • 试验注册号NCT02592707,2015年10月30日注册。

主要发现

  • 中位累积给药活度13.0 GBq(3周期),A部分13.1 GBq,B部分12.9 GBq。
  • 17例(42.5%)患者发生≥3级治疗相关不良事件,最常见为淋巴细胞减少、血小板减少和中性粒细胞减少。
  • 未观察到3/4级肾毒性。
  • 2例患者发生研究者认为与治疗相关的髓系肿瘤。
  • A部分与B部分合计疾病控制率94.7%(95%CI 82.3–99.4),总缓解率21.1%(95%CI 9.6–37.3)。

关键数值与推荐

  • A部分固定给药方案为4.5 GBq/300 μg每周期,共3周期。
  • B部分给药活度为4.5或6.0 GBq/周期,肽量为300、700或1300 μg/周期,周期数1–5。
  • 肾脏累积吸收剂量限23 Gy,骨髓累积吸收剂量限1.5 Gy。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文报告2例患者发生研究者认为与治疗相关的髓系肿瘤。
  • 原文指出一项5年长期随访研究正在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [177Lu]Lu-satoreotide tetraxetan in 40 patients with previously treated, progressive neuroendocrine tumours (NETs), in which dosimetry was used to guide maximum administered activity. METHODS: This study was conducted in two parts. Part A consisted of 15 patients who completed three cycles of [177Lu]Lu-satoreotide tetraxetan at a fixed administered activity and peptide amount per cycle (4.5 GBq/300 µg). Part B, which included 25 patients who received one to five cycles of [177Lu]Lu-satoreotide tetraxetan, evaluated different administered activities (4.5 or 6.0 GBq/cycle) and peptide amounts (300, 700, or 1300 μg/cycle), limited to a cumulative absorbed radiation dose of 23 Gy to the kidneys and 1.5 Gy to the bone marrow. RESULTS: Median cumulative administered activity of [177Lu]Lu-satoreotide tetraxetan was 13.0 GBq over three cycles (13.1 GBq in part A and 12.9 GBq in part B). Overall, 17 (42.5%) patients experienced grade ≥ 3 treatment‑related adverse events; the most common were lymphopenia, thrombocytopenia, and neutropenia. No grade 3/4 nephrotoxicity was observed. Two patients developed myeloid neoplasms considered treatment related by the investigator. Disease control rate for part A and part B was 94.7% (95% confidence interval [CI]: 82.3-99.4), and overall response rate was 21.1% (95% CI: 9.6-37.3). CONCLUSION: [177Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three cycles, has an acceptable safety profile with a promising clinical response in patients with progressive, SSTR-positive NETs. A 5-year long-term follow-up study is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02592707. Registered October 30, 2015.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wild D, Grønbæk H, Navalkissoor S, et al. A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2023. PMID: 37721581. doi:10.1007/s00259-023-06383-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。